Abbott Laboratories (ABT) - Stock Report

The key macro issue is not healthcare demand in isolation, but whether procedure volumes, reimbursement and adoption keep feeding Abbott’s Medical Devices profit pool while Exact Sciences debt, integration cost and interest expense are reduced fast enough for growth to become post-capex free cash flow per share.

Q1 2026 gave investors a mixed but useful proof set. Sales rose 7.8% on a reported basis to $11.164 bn, and comparable sales growth was 3.7%, with Medical Devices still carrying the value bridge at $5.539 bn of sales and 8.5% comparable growth. Established Pharmaceuticals grew 9.0% excluding currency, while Nutrition fell 7.7% on a comparable basis after pricing actions and lower volumes. Diagnostics grew only 1.8% on a comparable basis; the Exact Sciences acquisition contributed $96 mn of Cancer Diagnostics sales from the March 23 closing date, so the quarter should not be annualized mechanically. Cash was the harder proof point: Q1 operating cash flow of $1.315 bn less $399 mn of capex left about $916 mn of post-capex cash for the quarter, below the $1.278 bn spent on dividends and buybacks. That shortfall is not a full-year conclusion, but it is the clearest near-term proof item after Abbott added Exact Sciences debt.

Abbott is a diversified global healthcare manufacturer, not a pure drug-discovery company. Its four operating engines play different roles: Medical Devices is the growth and margin engine; Diagnostics is the installed-base and laboratory-throughput engine now expanded into cancer screening; Nutrition is a branded consumer-health and clinical-nutrition cash stabilizer; Established Pharmaceuticals is an emerging-market branded-generics platform sold outside the United States.

That mix matters because Abbott earns its premium from product reliability, installed equipment, physician workflow, reimbursement access, manufacturing quality and global distribution rather than from a single blockbuster product cycle. Medical Devices includes rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care. Diabetes Care is anchored by FreeStyle Libre and the broader continuous-glucose-monitoring platform, while the cardiovascular device businesses depend on procedure volumes and specialist adoption.

Diagnostics is no longer only a pandemic-testing unwind story. Core Laboratory and Alinity-related testing remain the recurring base, Rapid and Molecular Diagnostics is still exposed to respiratory-testing volatility, and Exact Sciences adds oncology diagnostics through Cologuard, Oncotype DX and Cancerguard. The value stack is broader, but it now demands integration proof: oncology diagnostics must add durable test volume and data-enabled screening economics without letting acquisition amortization, interest and integration costs absorb the benefit.